POSFREA Drug Patent Profile
✉ Email this page to a colleague
When do Posfrea patents expire, and when can generic versions of Posfrea launch?
Posfrea is a drug marketed by Avyxa Holdings and is included in one NDA.
The generic ingredient in POSFREA is palonosetron hydrochloride. There are twenty-one drug master file entries for this compound. Twenty-one suppliers are listed for this compound. Additional details are available on the palonosetron hydrochloride profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Posfrea
A generic version of POSFREA was approved as palonosetron hydrochloride by SANDOZ on October 13th, 2015.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for POSFREA?
- What are the global sales for POSFREA?
- What is Average Wholesale Price for POSFREA?
Summary for POSFREA
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 1 |
| What excipients (inactive ingredients) are in POSFREA? | POSFREA excipients list |
| DailyMed Link: | POSFREA at DailyMed |
Pharmacology for POSFREA
| Drug Class | Serotonin-3 Receptor Antagonist |
| Mechanism of Action | Serotonin 3 Receptor Antagonists |
US Patents and Regulatory Information for POSFREA
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Avyxa Holdings | POSFREA | palonosetron hydrochloride | SOLUTION;INTRAVENOUS | 203050-001 | Mar 1, 2016 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Avyxa Holdings | POSFREA | palonosetron hydrochloride | SOLUTION;INTRAVENOUS | 203050-002 | Mar 1, 2016 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
